Stem Cell Research & Therapy (May 2018)

Human platelet lysate in mesenchymal stromal cell expansion according to a GMP grade protocol: a cell factory experience

  • Valentina Becherucci,
  • Luisa Piccini,
  • Serena Casamassima,
  • Silvia Bisin,
  • Valentina Gori,
  • Francesca Gentile,
  • Riccardo Ceccantini,
  • Elena De Rienzo,
  • Barbara Bindi,
  • Paola Pavan,
  • Vanessa Cunial,
  • Elisa Allegro,
  • Stefano Ermini,
  • Francesca Brugnolo,
  • Giuseppe Astori,
  • Franco Bambi

DOI
https://doi.org/10.1186/s13287-018-0863-8
Journal volume & issue
Vol. 9, no. 1
pp. 1 – 10

Abstract

Read online

Abstract Background The use of platelet lysate (PL) for the ex-vivo expansion of mesenchymal stromal/stem cells (MSCs) was initially proposed by Doucet et al. in 2005, as an alternative to animal serum. Moreover, regulatory authorities discourage the use of fetal bovine serum (FBS) or other animal derivatives, to avoid risk of zoonoses and xenogeneic immune reactions. Even if many studies investigated PL composition, there still are some open issues related to its use in ex-vivo MSC expansion, especially according to good manufacturing practice (GMP) grade protocols. Methods As an authorized cell factory, we report our experience using standardized PL produced by Azienda Ospedaliero Universitaria Meyer Transfusion Service for MSC expansion according to a GMP grade clinical protocol. As suggested by other authors, we performed an in-vitro test on MSCs versus MSCs cultured with FBS that still represents the best way to test PL batches. We compared 12 MSC batches cultured with DMEM 5% PL with similar batches cultured with DMEM 10% FBS, focusing on the MSC proliferation rate, MSC surface marker expression, MSC immunomodulatory and differentiation potential, and finally MSC relative telomere length. Results Results confirmed the literature data as PL increases cell proliferation without affecting the MSC immunophenotype, immunomodulatory potential, differentiation potential and relative telomere length. Conclusions PL can be considered a safe alternative to FBS for ex-vivo expansion of MSC according to a GMP grade protocol. Our experience confirms the literature data: a large number of MSCs for clinical applications can be obtained by expansion with PL, without affecting the MSC main features. Our experience underlines the benefits of a close collaboration between the PL producers (transfusion service) and the end users (cell factory) in a synergy of skills and experiences that can lead to standardized PL production.

Keywords